Compare American Airlines Group Inc (AAL) vs ACADIA Pharmaceuticals Inc. (ACAD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs ACADIA Pharmaceuticals Inc. — how do they compare? American Airlines Group Inc trades at $15.44 (market cap $10.55B), while ACADIA Pharmaceuticals Inc. trades at $29.84 (market cap $5.07B). The key difference: American Airlines Group Inc is far larger — about 2.1× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, American Airlines Group Inc nearer its low. Which is the better fit depends on your goals.
| AAL | ACAD | |
|---|---|---|
Market Cap | $10.55B | $5.07B |
Sector | Industrials | Health |
52-Week High | $18.15 | $29.41 |
52-Week Low | $10.18 | $20.06 |
Enterprise Value | $38.51B | $4.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAL trades at $15.00, down 5.9% in the last 24 hours, with technical indicators signaling a bearish trend near support at $14. The company reported mixed earnings, beating estimates in Q1 and Q2 2026 but missing in Q4 2025, with revenue growth to $54.63 billion in 2025. However, net income margin remains negative at -0.56%, and high debt levels persist despite a declining trend.
AAL's outlook is cautious; while analyst consensus is a buy with a $19.63 price target, risks include volatile fuel costs, leverage, and thin profitability. The stock offers potential upside if premium revenue growth sustains, but investors face headwinds from operational margins and economic sensitivity.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →
